Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation.

Graft versus host disease (GVHD) following solid organ transplantation is a rare but often fatal complication arising when donor immune cells contained within the graft recognise recipient tissues as ...

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of ...

Southeast Health has used funds raised during their 2025 Champions of Hope event to buy a blood irradiator, a piece of ...